Monoclonal Antibody handling

PLEASE NOTE:   Posts made to this forum should not be considered as the expressed opinions of, nor should be considered endorsed by, the Medication Safety Officer’s Society (MSOS) or the Institute for Safe Medication Practices (ISMP). 

Make sure your email is up-to-date
In order to continue to receive updates from MSOS, as well as forum posts and other valuable information as a member of MSOS, please be sure to update your email address with us, whenever it changes. If you need assistance doing so, please send an email to jrufo@ismp.org. 

2 posts / 0 new
Log in or register to post comments
Last post
Wed, 04/26/2017 - 09:23
#1
Emily K D'Anna
Emily K D'Anna's picture
Offline
Last seen: 2 weeks 3 days ago
Joined: 02/07/2017 - 11:38
Monoclonal Antibody handling

Hello!

Our institution has started a discussion around what PPE and preparation precautions should be in place for monoclonal antibodies (in both the inpatient and ambulatory setting). We recognize that the only monoclonal antibodies that fall on the NIOSH hazardous drug list include those that are conjugated to an antineoplastic (eg, gemtuzumab)... whereas other commonly used mAbs (eg, infliximab, omalizumab-outpatient) are not present in the list. (I did attach two articles that leaned towards treating these agents as hazardous medications.)

Would you please comment on how you prepare / handle monoclonal antibodies throughout your healthcare system (specifically those mAbs that are NOT already listed on the NIOSH list; including PPE requirements, who can prepare, location of preparation)?

Any information is greatly appreciated - thank you in advance for any insight or experience you are able to share.

Sincerely,
Emily

Attach files :
PDF icon j_oncol_pharm_pract_2016_apr_22_2_219-27.pdf

Tags: 

Top